Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What NATCOPHARM guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 18 Aug 2026 | NATCO Pharma filed the transcript of its Q1 FY27 earnings conference call held on August 14, 2026. Management (CFO Amit Parekh) reported consolidated total revenue of INR794.4 crores versus INR1,390.6 crores a year earlier, mainly due to lower Lenalidomide revenue, and EBITDA including other income of INR245.7... NSE copy | No results filed since | ||
| 04 Jun 2026 | Transcript of NATCO Pharma's Q4 FY26 earnings conference call held May 29, 2026, filed under Regulation 30. Management said consolidated revenue for FY26 was INR4,375.9 crores (vs INR4,784 crores) and net profit INR1,418.5 crores (vs INR1,883.4 crores); Q4 revenue was INR816.9 crores (vs INR1,287.3 crores) and Q4... NSE copy | -57.0 % | -44.7 % | -1.5 % |
| 18 Feb 2026 | NATCO Pharma filed the transcript of its Q3 and FY26 earnings conference call held on February 12, 2026. Management reported consolidated total revenue of INR705.4 crores for the quarter ended December 31, 2025, against INR651.1 crores a year earlier, EBITDA of INR216.8 crores (30.7% margin) and consolidated net... NSE copy | -34.1 % | -39.5 % | -8.1 % |
| 20 Nov 2025 | NATCO Pharma filed the transcript of its Q2 FY26 earnings conference call held on November 14, 2025 (quarter ended September 30, 2025). Management said consolidated total revenue was Rs 1,463 crores against Rs 1,434.9 crores a year earlier, EBITDA was Rs 679.2 crores (46.4% margin), and consolidated net profit was... NSE copy | +13.9 % | +36.3 % | -1.9 % |
| 19 Aug 2025 | Natco Pharma filed the transcript of its Q1 FY26 earnings conference call held on 13 August 2025 (quarter ended 30 June 2025). Management reported consolidated total revenue of INR1,390.6 crores (vs INR1,410.7 crores a year earlier), EBITDA of INR632.7 crores with a 45.5% margin, and consolidated net profit of... NSE copy | -23.5 % | -0.6 % | +1.0 % |
| 04 Jun 2025 | NATCO Pharma filed the transcript of its Q4 and FY25 earnings conference call held on May 29, 2025. Management reported FY25 consolidated total revenue of INR4,784 crores (up about 16% from INR4,126.9 crores) and consolidated net profit of INR1,883.4 crores (up 36% from INR1,388.3 crores). Management said Q4 FY25... NSE copy | -28.1 % | -2.5 % | +1.8 % |
| 19 Feb 2025 | Natco Pharma filed the transcript of its Q3 FY25 earnings conference call held on February 13, 2025. Management said consolidated total revenue was Rs 651.1 crore for the quarter ended December 31, 2024, against Rs 795.6 crore a year earlier, and consolidated net profit was Rs 132.4 crore against Rs 212.7 crore.... NSE copy | +5.3 % | +14.3 % | +3.6 % |
| 21 Nov 2024 | NATCO Pharma filed the transcript of its Q2 FY25 earnings conference call held on 13 November 2024, as required under Regulation 30 of the SEBI LODR Regulations. Management said consolidated total revenue for Q2 FY25 (quarter ended 30 September 2024) was INR 1,434.9 crores, against INR 1,060.8 crores a year... NSE copy | -37.5 % | -37.4 % | -20.0 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 09 Sep 2026 | Legal or regulatory, Management change | Board of Natco Pharma approved a rights issue of fully paid equity shares of face value ₹2 each for an amount not exceeding ₹1,300 crore, with the record date to be determined later. Board constituted a Fund-Raising Committee comprising V.C. Nannapaneni (Chairman), Rajeev Nannapaneni and P.S.R.K. Prasad, and... NSE copy |
| 14 Aug 2026 | Legal or regulatory | NATCO Pharma filed its Q1 FY27 earnings presentation for the quarter ended 30 June 2026. Consolidated total revenue for Q1 FY27 was INR 7,944 Mn, against INR 8,169 Mn in Q4 FY26 and INR 13,906 Mn in Q1 FY26 (figures as printed). EBITDA for Q1 FY27 was INR 2,457 Mn, an EBITDA margin of 30.9%, against 25.1% in Q4... NSE copy |
| 14 Aug 2026 | Legal or regulatory, Management change | Board outcome for the meeting held 14 August 2026: unaudited standalone and consolidated results for the quarter ended 30 June 2026 approved, with consolidated total revenue of INR 794.4 crore (vs INR 1,390.6 crore a year earlier) and consolidated net profit of INR 206.5 crore (vs INR 480.3 crore). Board declared... NSE copy |
| 29 May 2026 | Legal or regulatory | NATCO Pharma filed its Q4 FY26 and FY26 earnings investor presentation for the quarter and year ended 31 March 2026. Q4 FY26: total revenue INR 8,169 Mn, EBITDA INR 2,054 Mn (25.1% margin), profit after tax INR 2,690 Mn (36.4% margin per the presentation's highlights, including a one-time tax benefit of INR 1,150... NSE copy |
| 29 May 2026 | Legal or regulatory | Outcome of board meeting held on 29 May 2026 (meeting 11:45 a.m. to 14:05 p.m.), filed with BSE and NSE. The board approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 under Ind AS and Regulation 33 of the Listing Regulations, with the statutory auditor BS... NSE copy |
| 24 Mar 2026 | Legal or regulatory | The Board of NATCO Pharma Limited approved a Scheme of Arrangement under Sections 230-232 of the Companies Act, 2013, demerging its Agrochemicals Undertaking into wholly owned subsidiary Natco Crop Health Sciences Limited, with an appointed date of 1 October 2026. Share entitlement: 1 equity share of INR 2 in the... NSE copy |
| 18 Feb 2026 | Legal or regulatory | NATCO Pharma filed the transcript of its Q3 and FY26 earnings conference call held on February 12, 2026. Management reported consolidated total revenue of INR705.4 crores for the quarter ended December 31, 2025, against INR651.1 crores a year earlier, EBITDA of INR216.8 crores (30.7% margin) and consolidated net... NSE copy |
| 12 Feb 2026 | Legal or regulatory, Management change | Board outcome for the quarter and nine months ended 31 December 2025: unaudited standalone and consolidated results approved; consolidated revenue from operations Rs 6,473 million for the quarter and Rs 33,392 million for nine months; consolidated profit for the period Rs 1,513 million for the quarter (Rs 11,495... NSE copy |
| 12 Feb 2026 | Management change | Board meeting outcome dated 12 February 2026: approved unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Consolidated revenue from operations for Q3 FY26 was Rs 6,473 million, against Rs 4,748 million a year earlier; net profit attributable to owners was Rs 1,515... NSE copy |
| 29 Nov 2025 | Legal or regulatory, Credit rating | NATCO Pharma Limited filed intimation under Regulation 30 of SEBI LODR that ICRA Limited reaffirmed or assigned its credit ratings on November 28, 2025. Ratings on all instruments are [ICRA]AA (Stable) for long-term and [ICRA]A1+ for short-term; the total rated amount rose from Rs. 1,550.00 crore to Rs. 2,150.00... NSE copy |
| 19 Aug 2025 | Legal or regulatory | Natco Pharma filed the transcript of its Q1 FY26 earnings conference call held on 13 August 2025 (quarter ended 30 June 2025). Management reported consolidated total revenue of INR1,390.6 crores (vs INR1,410.7 crores a year earlier), EBITDA of INR632.7 crores with a 45.5% margin, and consolidated net profit of... NSE copy |
| 23 Jul 2025 | Legal or regulatory | NATCO Pharma's board, meeting held on 23 July 2025, approved acquiring 51,643,319 shares (35.75% including its prior 0.80% holding) of Adcock Ingram Holdings Limited, South Africa, at ZAR 75.00 per share, for a total investment cost of about Rs 2,000 crore. The board also approved incorporating a wholly owned... NSE copy |
| 04 Jun 2025 | Legal or regulatory | NATCO Pharma filed the transcript of its Q4 and FY25 earnings conference call held on May 29, 2025. Management reported FY25 consolidated total revenue of INR4,784 crores (up about 16% from INR4,126.9 crores) and consolidated net profit of INR1,883.4 crores (up 36% from INR1,388.3 crores). Management said Q4 FY25... NSE copy |
| 28 May 2025 | Legal or regulatory | Board of NATCO Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 under Ind AS, along with auditor's reports (unmodified opinion). The Board approved appointment of BK & Associates, Practicing Company Secretaries, as Secretarial Auditors for... NSE copy |
| 12 Feb 2025 | Legal or regulatory | NATCO Pharma filed its Q3 FY25 earnings presentation for the quarter and nine months ended December 31, 2024. Q3 FY25 consolidated total revenue was INR 6,511 Mn (vs INR 7,956 Mn in Q3 FY24), EBITDA was INR 2,151 Mn with a 33.0% margin, and profit after tax was INR 1,324 Mn (vs INR 2,127 Mn in Q3 FY24). Pharma... NSE copy |
| 12 Feb 2025 | Management change | NATCO Pharma announced unaudited consolidated results for the quarter and nine months ended 31-12-2024: Q3 revenue from operations Rs 4,748 million (Rs 7,586 million in Q3 FY24), net profit Rs 1,324 million (Rs 2,127 million), basic EPS Rs 7.43; nine-month revenue Rs 32,085 million and net profit Rs 14,774 million.... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (16 in all). A list of what was filed, not a judgement of the company.